Amphastar Pharmaceuticals, Inc. (AMPH) vs Replimune Group, Inc. (REPL)
A side-by-side comparison of Amphastar Pharmaceuticals, Inc. and Replimune Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMPH
Amphastar Pharmaceuticals, Inc.
$25.59HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
REPL
Replimune Group, Inc.
$13.11HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — AMPH vs REPL
growth of $100 · dividends reinvested · last 8yAMPH +52.5% (+5.4%/yr)REPL -13.3% (-1.8%/yr)AMPH compounded faster over this window
AMPH REPL
AMPH vs REPL: by the numbers
- •AMPH is the larger company ($1.13B vs $1.10B market cap).
- •AMPH is profitable (10.76% net margin) while REPL runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | AMPH | REPL |
|---|---|---|
| P/E ratio | 15.14 | N/A |
| Forward P/E | 8.61 | N/A |
| PEG ratio | 0.11 | N/A |
| P/S ratio | 1.55 | N/A |
| P/B ratio | 1.47 | 10.43 |
| EV / EBITDA | 8.87 | N/A |
| FCF yield | 13.55% | N/A |
Profitability
| Metric | AMPH | REPL |
|---|---|---|
| Gross margin | 47.68% | 0.00% |
| Operating margin | 15.66% | 0.00% |
| Net margin | 10.76% | 0.00% |
| ROE | 10.23% | -281.14% |
| ROIC | 5.93% | -139.11% |
Growth (annualized)
| Metric | AMPH | REPL |
|---|---|---|
| Revenue CAGR (5Y) | 13.71% | N/A |
| EPS CAGR (5Y) | 134.23% | N/A |
| FCF CAGR (5Y) | 23.90% | N/A |
| Total return CAGR (5Y) | 6.13% | -15.17% |
Frequently asked
- Is AMPH or REPL more profitable?
- AMPH runs the higher net margin — AMPH at 10.76% versus REPL at 0.00%.
- How have AMPH and REPL total returns compared?
- Over the past 5 years, AMPH delivered 6.13% and REPL delivered -15.17% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Amphastar Pharmaceuticals P/E ratioAmphastar Pharmaceuticals ROEReplimune ROEAmphastar Pharmaceuticals operating marginReplimune operating marginAmphastar Pharmaceuticals revenue growthReplimune revenue growthAmphastar Pharmaceuticals free cash flowReplimune free cash flow
Amphastar Pharmaceuticals & Replimune appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.